• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

On the turnaround trail, tiny Corbus pays $7.5M for rival to Seagen's oncology ADC Padcev

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Feb 13, 2023 at 10:52: AM
via Corbus Pharmaceuticals is mounting a David vs. Goliath battle against Seagen, spending $7.5 million of its dwindling cash reserves on a challenger to the nectin-4 antibody-drug conjugate (ADC) Padcev.

article source
 




Top Bottom
Back
Quote